Lauren Elizabeth Colbert

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Cullen M. Taniguchi · 5 shared papers, 2017–2023 · strength 0.43
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
2. Gabriel Oliveira Sawakuchi · 4 shared papers, 2017–2023 · strength 0.34
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
   • Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
3. Jerome Carl Landry · 8 shared papers, 2013–2015 · strength 0.29
   • Paper High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected… DOI 10.1016/j.ijrobp.2014.11.004↗
   • Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
   • Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
4. Joseph M. Herman · 3 shared papers, 2018–2023 · strength 0.29
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
5. Shalini Moningi · 3 shared papers, 2018–2023 · strength 0.29
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
6. Eugene Jon Koay · 3 shared papers, 2018–2023 · strength 0.27
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
   • Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
7. William Adrian Hall · 7 shared papers, 2013–2014 · strength 0.24
   • Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
   • Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
   • Paper The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. DOI 10.1002/cncr.28047↗
8. David A. Kooby · 7 shared papers, 2013–2014 · strength 0.24
   • Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
   • Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
   • Paper The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. DOI 10.1002/cncr.28047↗
9. Brian G. Czito · 2 shared papers, 2020–2023 · strength 0.21
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
10. Jessica M. Frakes · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
11. Todd Anthony Aguilera · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
12. Manisha Palta · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
13. Rebecca S. Slack Tidwell · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
14. Sarah E. Hoffe · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
15. Manoop S. Bhutani · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
16. Ying Yuan · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
17. Shubham Pant · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
18. Ching-Wei David Tzeng · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
19. Tara N. Fujimoto · 2 shared papers, 2017–2019 · strength 0.15
    • Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
    • Paper EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced… DOI 10.1101/195610↗
20. Volkan N. Adsay · 4 shared papers, 2013–2015 · strength 0.14
    • Paper High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected… DOI 10.1016/j.ijrobp.2014.11.004↗
    • Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
    • Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
21. Burcu Saka · 4 shared papers, 2013–2015 · strength 0.14
    • Paper High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected… DOI 10.1016/j.ijrobp.2014.11.004↗
    • Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
    • Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
22. Walter John Curran · 4 shared papers, 2013–2015 · strength 0.14
    • Paper High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected… DOI 10.1016/j.ijrobp.2014.11.004↗
    • Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
    • Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
23. Shishir Kumar Maithel · 4 shared papers, 2013–2015 · strength 0.14
    • Paper High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected… DOI 10.1016/j.ijrobp.2014.11.004↗
    • Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
    • Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
24. Bassel F. El‐Rayes · 4 shared papers, 2013–2015 · strength 0.14
    • Paper High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected… DOI 10.1016/j.ijrobp.2014.11.004↗
    • Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
    • Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
25. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.